Radioiodine for remnant ablation and therapy of metastatic disease. - Wikidata - wikimedia - TriplyDB

Radioiodine for remnant ablation and therapy of metastatic disease.

Radioiodine for remnant ablation and therapy of metastatic disease.

http://www.wikidata.org/entity/Q37913996

about

German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.Sterol regulatory element-binding proteins are regulators of the NIS gene in thyroid cells.Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper Mechanism of anion selectivity and stoichiometry of the Na+/I- symporter (NIS).Is the image quality of I-124-PET impaired by an automatic correction of prompt gammas?Modulation of sodium iodide symporter in thyroid cancer SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model Choroidal metastasis from follicular cell thyroid carcinoma masquerading as circumscribed choroidal haemangioma.Differentiated thyroid cancer-personalized therapies to prevent overtreatment.The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.Physiological sodium concentrations enhance the iodide affinity of the Na+/I- symporter.Not all DTC patients with N positive disease deserve the attribution "high risk". Contribution of the MSDS trial.Effects of recombinant human thyroid stimulating hormone on (131)I therapy for the treatment of differentiated thyroid cancer.Radioiodide induces apoptosis in human thyroid tissue in culture.Automated MicroSPECT/MicroCT Image Analysis of the Mouse Thyroid Gland.Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer.Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.

P2860

Q30317867-62985D88-3763-40DD-9B10-D9C7FE2999EB Q33635793-3B1D085A-696B-4233-B815-2A7C1ECDDF64 Q33825202-DA55E0D7-47FC-4EA0-B083-AD7A4314E07D Q34225585-4D512EDF-6E7A-40AE-A30E-8CA1DE715644 Q34981083-6A77C76D-3B30-45ED-AEA0-A124005D59A5 Q35690173-773D4777-C93B-43DE-ABB1-436C9B2A5493 Q37123127-47EC4019-C605-4BCA-865D-3924A5C97CDB Q38205443-B16016C9-EF4E-4A5E-A9DA-20F78A0EF152 Q38224994-14386455-8AFB-4F2D-B8F3-AC6564BA7A78 Q38230269-78A9E9A3-7D65-43EF-8A84-BD3732AD2948 Q38989161-DB392B2A-AA4F-41BF-8359-0B90F7BA4C69 Q41669650-2E0B6A88-DD2E-4A79-A2AA-B4B00F473618 Q41914116-7BECB00B-E8C8-4A0C-957D-A6BFF42DE22C Q45944006-43D3785D-F2F0-4CAE-BBC7-69A32EF542DB Q47664896-6E5329F5-EE09-4A85-A953-5320CBD339F4 Q47994657-16AF995D-54F1-4C44-B655-329A3B403A20 Q54217447-8E2D4BCF-0B87-4615-A558-400CF988DF55

P2860

Radioiodine for remnant ablation and therapy of metastatic disease.

http://www.wikidata.org/entity/Q37913996

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Radioiodine for remnant ablation and therapy of metastatic disease.

@en

Radioiodine for remnant ablation and therapy of metastatic disease.

@nl

type

label

Radioiodine for remnant ablation and therapy of metastatic disease.

@en

Radioiodine for remnant ablation and therapy of metastatic disease.

@nl

prefLabel

Radioiodine for remnant ablation and therapy of metastatic disease.

@en

Radioiodine for remnant ablation and therapy of metastatic disease.

@nl

P1433

Q37913996-B417DEB0-7820-4064-BD54-6CD3733172EF

P1476

Q37913996-073E411C-DD82-4574-88AF-627AF216CFF4

P2093

Q37913996-24D19EE5-0B61-4AEC-8419-434324C193DF

Q37913996-258EA2EC-949C-4CF1-820B-5EB84FE89521

Q37913996-73115C7D-6D84-423B-8853-87D29D04D483

Q37913996-C4E852AE-5E3D-4901-BF00-603FCCC0E8D5

Q37913996-E98843B5-76E7-45E3-B43C-F58B5225B57A

P2860

Q37913996-009A047B-F241-4A90-AF72-90C332DDB126

Q37913996-0868C344-F6E1-4BEB-BE63-9D82216D323F

Q37913996-099DC4B9-54EE-4789-B6BD-53AF40011960

Q37913996-0C9BC025-E02D-45AC-85D8-879D509A1B7D

Q37913996-0CEE60AA-94AE-46A7-910C-9782381BC8B2

Q37913996-1D8891E6-BD91-49C0-9A2C-BE5332C9452B

Q37913996-32F06D6A-6CA7-4F12-8DA5-B7B59965394F

Q37913996-340BA06E-6877-486C-8A6C-2B675A54BB6A

Q37913996-35C6F223-0F1E-41CF-A1EE-C5716BA8FF52

Q37913996-3C0D26A5-8A00-4CC6-82F4-FA2C5F3A21EC

P2888

Q37913996-F9F60FA1-53DA-4054-8045-C78AF32F6F20

P304

Q37913996-B0DB4B2C-0A40-461E-A8FA-2E07EBF19CBB

P31

Q37913996-25ED9650-2FCD-454C-9E27-D4B357E393B9

P356

Q37913996-21B74797-A34C-4227-AC98-160E21272383

P433

Q37913996-32C623AD-68E7-4207-B8C4-2EB737873FF3

P478

Q37913996-348C054C-1FCC-408E-BE33-C3C96749F829

P577

Q37913996-A1412BF1-7512-4DAF-9A16-A204B25A7817

P6179

Q37913996-8CB2686D-17C7-4020-B8EC-6E19D4855596

P698

Q37913996-703CC0E3-664F-4310-BD82-70C142EBEAD4

P356

NRENDO.2011.134

P1433

Nature Reviews Endocrinology

P1476

Radioiodine for remnant ablation and therapy of metastatic disease.

@en

P2093

Christoph Reiners

http://www.w3.org/2001/XMLSchema#string

Frederik A Verburg

http://www.w3.org/2001/XMLSchema#string

Heribert Hänscheid

http://www.w3.org/2001/XMLSchema#string

Markus Luster

http://www.w3.org/2001/XMLSchema#string

Michael Lassmann

http://www.w3.org/2001/XMLSchema#string

P2860

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.

Development and in vitro characterization of human recombinant thyrotropin.

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma.

Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.

The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.

Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report.

P2888

nrendo.2011.134

P304

589-595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRENDO.2011.134

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1028254145

http://www.w3.org/2001/XMLSchema#string

P698

21826102

http://www.w3.org/2001/XMLSchema#string